Dr Reddy's Laboratories fell 0.17% to Rs 3,175.35 after the US drug regulator issued a Form 483 with three observations to the drug major's API manufacturing plant in Telangana.
"The audit of our API Manufacturing Plant - 5 at Miryalaguda, Nalgonda District, Telangana, by the US FDA, has been completed today. We have been issued a Form 483 with 3 (Three) observations. We will address them comprehensively within the stipulated timeline," Dr Reddy's Laboratories said in a statement on Thursday, 5 March 2020.Shares of Dr Reddy's Laboratories jumped 9.84% in the past three trading sessions to settle at Rs 3,180.75 yesterday, 5 March 2020, from its close of Rs 2,895.75 on 2 March 2020.
On a consolidated basis, Dr Reddy's Laboratories reported a net loss of Rs 538.40 crore in Q3 December 2019 compared with a net profit of Rs 500.30 crore in Q3 December 2018. Net sales rose 13.9% to Rs 4,383.80 crore in Q3 December 2019 over Q3 December 2018.
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
